Overcoming prostate cancer drug resistance with a novel organosilicon small molecule

A major challenge to the treatment of advanced prostate cancer (PCa) is the development of resistance to androgen-deprivation therapy (ADT) and chemotherapy. It is imperative to discover effective therapies to overcome drug resistance and improve clinical outcomes. We have developed a novel class of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Rui, Ma, Xiaowei, Bai, Lijuan, Li, Xin, Mamouni, Kenza, Yang, Yang, Liu, HongYan, Danaher, Alira, Cook, Nicholas, Kucuk, Omer, Hodges, Robert S., Gera, Lajos, Wu, Daqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604682/
https://www.ncbi.nlm.nih.gov/pubmed/34781084
http://dx.doi.org/10.1016/j.neo.2021.11.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604682/
https://www.ncbi.nlm.nih.gov/pubmed/34781084
http://dx.doi.org/10.1016/j.neo.2021.11.006

Ejemplares similares